To read the full story, subscribe or sign in.

Neuro3d's Third Round: EUR31.5M For Development Of Lead Drugs

Jan. 5, 2005

PARIS - Neuro3d closed a third round of financing in which it raised €31.5 million (US$41.6 million) from eight European venture capital funds. (BioWorld International)

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for Dec. 13, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 13, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Keros stock wilts as it halts two dosing arms in hypertension study

BioWorld

After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...

Upgrade your daily dose of biopharma and medtech news

Neuro3d's Third Round: EUR31.5M For Development Of Lead Drugs